MedTrace Logo

Probiotics and Allergic Diseases

NCT01635738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2015-09-02

No results posted yet for this study

Summary

Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus paracasei GMNL-133(LP), Lactobacillus fermentum GM-090 (LF), and Lactobacillus paracasei GMNL-133(LP) with Lactobacillus fermentum GM-090 (LF) combination products used for adjuvant treatment of atopic dermatitis and asthma.

Conditions

Interventions

BIOLOGICAL

LP GMNL-133 capsule

One capsule with 2x10\^9 (cfu) LP GMNL-133, once daily, PO

BIOLOGICAL

LF GM-090 capsule

Arm: LF GM-090 group One capsule with 2x10\^9 (cfu) LF GM-090, once daily, PO

BIOLOGICAL

LP GMNL-133 +LF GM-090 capsule

One capsule with 4x10\^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO

BIOLOGICAL

Placebo

Placebo

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • GenMont Biotech Incorporation

    lead INDUSTRY

Principal Investigators

  • I-Jen Wang, Doctor · Taipei Hospital, Department of Health, Taiwan, R.O.C.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635738 on ClinicalTrials.gov